UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2 -Overexpressing Metastatic Breast Cancer

Journal of clinical oncology, 2023-03, Vol.41 (9), p.1638-1645

2023

Volltextzugriff (PDF)

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Journal of clinical oncology, 2002-02, Vol.20 (3), p.719-726

Vogel, C. L.

2002

Volltextzugriff (PDF)

Abstract CT026: Phase I trial of HuMab-5B1 (MVT-5873), a novel monoclonal antibody targeting sLea, in patients with advanced pancreatic cancer and other CA19-9 positive malignancies

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.CT026-CT026

2016

Volltextzugriff (PDF)

Phase II Study of Direct Intralesional Gene Transfer of Allovectin-7, an HLA-B7/β2-Microglobulin DNA-Liposome Complex, in Patients with Metastatic Melanoma

Clinical cancer research, 2001-08, Vol.7 (8), p.2285-2291

2001

Volltextzugriff (PDF)

CVM-1118: An oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study

Journal of clinical oncology, 2024-08, Vol.42 (23_suppl), p.92-92

2024

Volltextzugriff (PDF)

CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e16150-e16150

2024

Volltextzugriff (PDF)

CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in patients with advanced neuroendocrine tumors (NETs)—A phase IIa study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e16235-e16235

2023

Volltextzugriff (PDF)

BNT321, a novel monoclonal antibody targeting sialyl Lewis A: Phase 1 monotherapy and combination with mFOLFIRINOX in patients with advanced CA19-9 expressing cancers

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.654-654

2024

Volltextzugriff (PDF)

MP43-02 CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): 18 MONTH FOLLOW-UP FROM A MULTICENTER PHASE II TRIAL

The Journal of urology, 2019-04, Vol.201 (Supplement 4)

2019

Volltextzugriff (PDF)

LBA24 CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): 12 MONTH INTERIM RESULTS FROM A MULTICENTER PHASE II TRIAL

The Journal of urology, 2018-04, Vol.199 (4), p.e1166-e1166

2018

Volltextzugriff (PDF)

Phase II Trial of Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial Cancer

Journal of clinical oncology, 2002-02, Vol.20 (4), p.937-940

Vaughn, D. J.

2002

Volltextzugriff (PDF)

Phase I dose escalation study of CVM-1118, a novel anti-vascular mimicry agent, in patients with advanced cancers

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.2580-2580

2017

Volltextzugriff (PDF)

Abstract CT140: Phase I dose escalation study of 177Lu-HuMab-5B1 (MVT-1075) in combination with MVT-5873 as radioimmunotherapy (RIT) in subjects with relapsed / refractory pancreatic cancer or other CA19-9+ malignancies

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.CT140-CT140

2018

Volltextzugriff (PDF)

HuMab-5B1 (MVT-5873), a mAb targeting sLe a , in combination with first-line gemcitabine plus nab-paclitaxel (gem/nab-P) for patients with pancreatic cancer (PDAC) and other CA19-9 positive malignancies

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e16235-e16235

2018

Volltextzugriff (PDF)

A phase Ib/II study of oral nanatinostat (N) and valganciclovir (VG) in subjects with Epstein-Barr virus (EBV)-associated lymphomas

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.7551-7551

2019

Volltextzugriff (PDF)

Abstract LB-B25: Preliminary phase I data comparing HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, as a single agent and in combination with first line nab-paclitaxel and gemcitabine in patients with CA19-9 positive pancreatic cancer

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.LB-B25-LB-B25

2018

Volltextzugriff (PDF)

Single agent HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLe a , in patients with pancreatic cancer and other CA19-9 positive malignancies

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.4110-4110

2017

Volltextzugriff (PDF)

Results From a Randomized Phase III Study Comparing Combined Treatment With Histamine Dihydrochloride Plus Interleukin-2 Versus Interleukin-2 Alone in Patients With Metastatic Melanoma

Journal of clinical oncology, 2002-01, Vol.20 (1), p.125-133

Agarwala, S. S.

2002

Volltextzugriff (PDF)

Targeting Hypoxia and AKR1C3 with PR104 in Patients with Acute Leukemia

Blood, 2012-11, Vol.120 (21), p.3615-3615

2012

Volltextzugriff (PDF)

Abstract B278: PR610: A novel hypoxia-selective tyrosine kinase inhibitor in phase I clinical trial

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.B278-B278

2013

Volltextzugriff (PDF)

Final report of phase I/II study of PR104, a hypoxia-activated pro-drug, in relapsed/refractory acute leukemia

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.7074-7074

2013

Volltextzugriff (PDF)

Monoclonal antibodies and cancer

Critical reviews in oncology/hematology, 2001-10, Vol.40 (1), p.1-2

Gutheil, John

2001

Volltextzugriff (PDF)

The promise of monoclonal antibodies for the therapy of cancer

Critical reviews in oncology/hematology, 2001-04, Vol.38 (1), p.1-2

Gutheil, John

2001

Volltextzugriff (PDF)

Phase I/II Study of PR104, a Bioreductive Prodrug, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Using Patient-Specific Adaptive Dose Selection

Blood, 2011-11, Vol.118 (21), p.1523-1523

2011

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(40)

Publikationsform

Sprache

Englisch
(50)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Humans
(14)
Oncology
(8)
Psychiatry
(5)
Biological And Medical Sciences
(4)
Antibodies, Monoclonal - Therapeutic Use
(3)
Forensic Psychiatry
(3)
Informed Consent
(3)
Medical Sciences
(3)
Privacy
(3)
United States
(3)
Antineoplastic Agents - Therapeutic Use
(2)
Confidently
(2)
Health Care Sciences & Services
(2)
Hematology
(2)
Mental Disorders - Therapy
(2)
Neoplasms - Drug Therapy
(2)
Oncogene
(2)
Pathology
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2 -Overexpressing Metastatic Breast Cancer

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Abstract CT026: Phase I trial of HuMab-5B1 (MVT-5873), a novel monoclonal antibody targeting sLea, in patients with advanced pancreatic cancer and other CA19-9 positive malignancies

Phase II Study of Direct Intralesional Gene Transfer of Allovectin-7, an HLA-B7/β2-Microglobulin DNA-Liposome Complex, in Patients with Metastatic Melanoma

CVM-1118: An oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study

CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study

CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in patients with advanced neuroendocrine tumors (NETs)—A phase IIa study

BNT321, a novel monoclonal antibody targeting sialyl Lewis A: Phase 1 monotherapy and combination with mFOLFIRINOX in patients with advanced CA19-9 expressing cancers

MP43-02 CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): 18 MONTH FOLLOW-UP FROM A MULTICENTER PHASE II TRIAL

LBA24 CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): 12 MONTH INTERIM RESULTS FROM A MULTICENTER PHASE II TRIAL

Phase II Trial of Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial Cancer

Phase I dose escalation study of CVM-1118, a novel anti-vascular mimicry agent, in patients with advanced cancers

Abstract CT140: Phase I dose escalation study of 177Lu-HuMab-5B1 (MVT-1075) in combination with MVT-5873 as radioimmunotherapy (RIT) in subjects with relapsed / refractory pancreatic cancer or other CA19-9+ malignancies

HuMab-5B1 (MVT-5873), a mAb targeting sLe a , in combination with first-line gemcitabine plus nab-paclitaxel (gem/nab-P) for patients with pancreatic cancer (PDAC) and other CA19-9 positive malignancies

A phase Ib/II study of oral nanatinostat (N) and valganciclovir (VG) in subjects with Epstein-Barr virus (EBV)-associated lymphomas

Abstract LB-B25: Preliminary phase I data comparing HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, as a single agent and in combination with first line nab-paclitaxel and gemcitabine in patients with CA19-9 positive pancreatic cancer

Single agent HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLe a , in patients with pancreatic cancer and other CA19-9 positive malignancies

Results From a Randomized Phase III Study Comparing Combined Treatment With Histamine Dihydrochloride Plus Interleukin-2 Versus Interleukin-2 Alone in Patients With Metastatic Melanoma

Targeting Hypoxia and AKR1C3 with PR104 in Patients with Acute Leukemia

Abstract B278: PR610: A novel hypoxia-selective tyrosine kinase inhibitor in phase I clinical trial

Final report of phase I/II study of PR104, a hypoxia-activated pro-drug, in relapsed/refractory acute leukemia

Monoclonal antibodies and cancer

The promise of monoclonal antibodies for the therapy of cancer

Phase I/II Study of PR104, a Bioreductive Prodrug, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Using Patient-Specific Adaptive Dose Selection

Aktive Filter

Suchergebnisse filtern